ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM

Aim. To assess the effect of meldonium (in combination with antihypertensive therapy) on the severity of asthenic syndrome (AS) in elderly patients with arterial hypertension (HT).Material and methods. Patients (n=180, >65 years old) with HT (grade 1–2) and secondary somatogenic AS (assessed...

Full description

Bibliographic Details
Main Authors: M. E. Statsenko, S. V. Nedogoda, S. V. Turkina, I. A. Tyshchenko, L. V. Poletaeva, V. V. Tsoma, A. A. Ledyaeva, E. V. Chumachok
Format: Article
Language:English
Published: Столичная издательская компания 2015-09-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/37
_version_ 1826949928501379072
author M. E. Statsenko
S. V. Nedogoda
S. V. Turkina
I. A. Tyshchenko
L. V. Poletaeva
V. V. Tsoma
A. A. Ledyaeva
E. V. Chumachok
author_facet M. E. Statsenko
S. V. Nedogoda
S. V. Turkina
I. A. Tyshchenko
L. V. Poletaeva
V. V. Tsoma
A. A. Ledyaeva
E. V. Chumachok
author_sort M. E. Statsenko
collection DOAJ
description Aim. To assess the effect of meldonium (in combination with antihypertensive therapy) on the severity of asthenic syndrome (AS) in elderly patients with arterial hypertension (HT).Material and methods. Patients (n=180, >65 years old) with HT (grade 1–2) and secondary somatogenic AS (assessed by the MFI-20 scale). The patients were randomized into 3 groups according to the scheme of treatment. Group 1 — intermittent treatment with meldonium (500 mg once daily for 3 months followed by a break 3 months; 2 courses). Group 2 — continuous treatment with meldonium (500 mg once daily for 12 months). Group 3 — control (receive only antihypertensive drugs). Evaluation of AS was assessed by MFI-20 scales at baseline and at week 52 of treatment.Results. AS signs attenuation was found in groups 1 and2. In group1 a number of patients with general asthenia decreased on 70.5% (p<0.05), with physical asthenia — on 47.7% (p<0.05), with reduced activity — on 33.3%, reduced motivation — on 25%. In group2 a number of patients with general asthenia decreased on 60% (p<0.05), physical asthenia — on 39.7%, reduced activity — on 79.9% (p<0.05), reduced motivation — on 12.2%, mental asthenia — on 77.7% (p<0.05). In group 3 no significant changes in these parameters were found. Moreover a number of patients with mental asthenia increased on 45.4% (p<0.05).Conclusion. Meldonium included into antihypertensive therapy can reduce the symptoms of secondary somatogenic AS. More pronounced antiasthenic effect can be achieved with meldonium taking regime 500 mg daily continuously for 52 weeks.
first_indexed 2024-03-08T14:07:37Z
format Article
id doaj.art-ff043c82477d4b2286e683c912f1fd1c
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2025-02-17T22:22:45Z
publishDate 2015-09-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-ff043c82477d4b2286e683c912f1fd1c2024-12-04T11:47:58ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0191253010.20996/1819-6446-2013-9-1-25-3037ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUMM. E. Statsenko0S. V. Nedogoda1S. V. Turkina2I. A. Tyshchenko3L. V. Poletaeva4V. V. Tsoma5A. A. Ledyaeva6E. V. Chumachok7Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityAim. To assess the effect of meldonium (in combination with antihypertensive therapy) on the severity of asthenic syndrome (AS) in elderly patients with arterial hypertension (HT).Material and methods. Patients (n=180, >65 years old) with HT (grade 1–2) and secondary somatogenic AS (assessed by the MFI-20 scale). The patients were randomized into 3 groups according to the scheme of treatment. Group 1 — intermittent treatment with meldonium (500 mg once daily for 3 months followed by a break 3 months; 2 courses). Group 2 — continuous treatment with meldonium (500 mg once daily for 12 months). Group 3 — control (receive only antihypertensive drugs). Evaluation of AS was assessed by MFI-20 scales at baseline and at week 52 of treatment.Results. AS signs attenuation was found in groups 1 and2. In group1 a number of patients with general asthenia decreased on 70.5% (p<0.05), with physical asthenia — on 47.7% (p<0.05), with reduced activity — on 33.3%, reduced motivation — on 25%. In group2 a number of patients with general asthenia decreased on 60% (p<0.05), physical asthenia — on 39.7%, reduced activity — on 79.9% (p<0.05), reduced motivation — on 12.2%, mental asthenia — on 77.7% (p<0.05). In group 3 no significant changes in these parameters were found. Moreover a number of patients with mental asthenia increased on 45.4% (p<0.05).Conclusion. Meldonium included into antihypertensive therapy can reduce the symptoms of secondary somatogenic AS. More pronounced antiasthenic effect can be achieved with meldonium taking regime 500 mg daily continuously for 52 weeks.https://www.rpcardio.online/jour/article/view/37elderly patientsarterial hypertensionsomatic asthenic syndromemeldonium
spellingShingle M. E. Statsenko
S. V. Nedogoda
S. V. Turkina
I. A. Tyshchenko
L. V. Poletaeva
V. V. Tsoma
A. A. Ledyaeva
E. V. Chumachok
ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM
Рациональная фармакотерапия в кардиологии
elderly patients
arterial hypertension
somatic asthenic syndrome
meldonium
title ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM
title_full ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM
title_fullStr ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM
title_full_unstemmed ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM
title_short ASTHENIC DISORDERS IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION: MANAGEMENT POTENTIAL OF MELDONIUM
title_sort asthenic disorders in elderly patients with arterial hypertension management potential of meldonium
topic elderly patients
arterial hypertension
somatic asthenic syndrome
meldonium
url https://www.rpcardio.online/jour/article/view/37
work_keys_str_mv AT mestatsenko asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium
AT svnedogoda asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium
AT svturkina asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium
AT iatyshchenko asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium
AT lvpoletaeva asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium
AT vvtsoma asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium
AT aaledyaeva asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium
AT evchumachok asthenicdisordersinelderlypatientswitharterialhypertensionmanagementpotentialofmeldonium